Company to showcase EsoGuard^® and EsoCheck^® at the conference's Innovation Pavilion

NEW YORK, Oct. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company and several of its key executives will be participating in the upcoming The MedTech Conference 2024, the world's foremost annual medical technology event, which will be held October 15-17, 2024, in Toronto, Canada. The MedTech Conference is organized by AdvaMed, the world's leading medical technology association. Lucid and its team will be highlighted at multiple conference venues and events.

Innovation Pavilion

Lucid has been selected to participate in the conference's prestigious Innovation Pavilion, a dedicated area within the MedTech Campus for device, diagnostic, and digital health companies to showcase their cutting-edge technologies. The Lucid team, led by Jessie Gifford, Lucid's Senior Director of Product Development & Manufacturing, will host live demonstrations of Lucid's EsoCheck^® Esophageal Cell Collection Device and showcase the performance of its EsoGuard^® Esophageal DNA Test, allowing conference attendees to experience firsthand how these innovative technologies seek to prevent esophageal cancer through widespread, early detection of esophageal precancer in at-risk patients.

CEOs Unplugged Event

Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will be featured at one of the conference's CEOs Unplugged events where he will be joined by distinguished panelists, including

• Caroline Irungu, Global VP of Medtech at Dassault Systemes;
• Jaime Wheeler, VP of Global Clinical Affairs at Edwards Lifesciences; and
• Jean-Claude Dubacher, Chairman and Chief Executive Officer of B. Braun of America Inc.

Dr. Aklog proudly represents Lucid and PAVmed in several key leadership positions within the AdvaMed organization. As a member of the Executive Committee of the AdvaMed Board of Directors, he contributes to strategic initiatives that advance the medical technology sector. He also serves on the AdvaMedDx Board of Directors, which focuses on the vital interests of diagnostic companies and as Chairman of the AdvaMed Accel Board of Directors, which supports the growth and development of small medical technology companies, such as Lucid.

Company Presentation

As part of the conference's Investor Forum, Shaun O'Neil, Lucid's President and Chief Operating Officer, will deliver Lucid's Company Presentation on Tuesday, October 15, 2024, from 3:45-3:55 PM.

"The MedTech Conference has become the world's leading annual event for the medical technology industry and offers Lucid the opportunity to engage with industry leaders, potential strategic partners, and investors who are shaping the future of healthcare," said Dr. Aklog. "We are excited to have been selected to exhibit in the Innovation Pavilion, where we will showcase our groundbreaking technologies, EsoGuard and EsoCheck, and to have a strong presence throughout the conference."

The MedTech Conference, organized by AdvaMed (the Advanced Medical Technology Association), is the premier annual event for the medical technology industry, with over 1,500 companies and attendees from 45 countries expected to participate this year. AdvaMed is the world largest medical technology association, representing over 500 companies that produce medical devices, diagnostic products, and health information systems. AdvaMed advocates for patient access to safe, effective, and innovative technologies that save and improve lives.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report.  Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-join-global-medtech-leaders-at-the-medtech-conference-2024-302269914.html

SOURCE Lucid Diagnostics